A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
Status:
Terminated
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
A 46-week study to compare the efficacy of relamorelin with that of placebo in participants
with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants
will either continue on relamorelin or placebo for 6 additional weeks.